Evaluation des pratiques des médecins généralistes du Maine et Loire concernant l hypertrophie bénigne de prostate

ANGERS-BU Médecine-Pharmacie (490072105) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Tolérance et faisabilité de la photothérapie dynamique par WST11 pour le traitement des cancers localisés de la prostate: Etude prospective sur 56 patients

ANGERS-BU Médecine-Pharmacie (490072105) / SudocSudocFranceF

Intérêt pronostique des antécédents familiaux de cancer prostatique et de cancer colique chez les patients atteints de cancer de la prostate

Cette thèse est fondée sur une étude regroupant 200 patients suivis au CHU d'Angers. C'est une étude épidémiogénétique, rétrospective, menée conjointement par le CeRePP sous la direction du Professeur CUSSENOT. Il s agissait de déterminer si les patients ayant des antécédents familiaux de cancer du côlon ou de cancer de la prostate étaient atteints de cancer de la prostate de moins bon pronostic que les patients sans antécédent. Il s'agissait également de déterminer si les cancers étaient plus précoces. Les résultats ont mis en évidence un âge de survenue du cancer de la prostate plus précoce de 2 ans et 2 mois en cas d'antécédent familial de même cancer par rapport à la population sans antécédents. En revanche, les antécédents de cancer colique n'ont pas influé sur l'âge de survenue des cancers de la prostate. En terme de pronostic, les résultats ont été plus contrastés et on ne retrouve pas de lien significatif entre les cancers les plus graves et la présence d'un antécédent familial de cancer de la prostate ou du côlon.ANGERS-BU Médecine-Pharmacie (490072105) / SudocSudocFranceF

L'étudiant hospitalier et la recherche biomédicale. Récit d'une expérience de participation à des travaux de recherche durant un stage d'externat

Contexte : L'externe n'a pas, au sein de l'hôpital universitaire, une place toujours favorable à son épanouissement intellectuel ou personnel. Exégèse : L'expérience rapportée cherche à montrer qu'en intégrant à des travaux de recherche un étudiant hospitalier, des objectifs pédagogiques de formation peuvent être atteints. Dans le cadre d'un stage d'externat dans un service d'urologie, un externe a été invité à participer à l'élaboration de plusieurs travaux dans le domaine de l'évaluation des pratiques et des essais thérapeutiques. Conclusion : Une telle expérience, en favorisant le processus d'intégration sociale et professionnelle de l'étudiant au sein de l'équipe, a eu des effets tangibles sur sa motivation à s'engager dans des activités d'apprentissage signifiantes

Hormonothérapie et risque cardiaque dans le traitement des cancers prostatiques. [Androgen deprivation and cardiovascular risk in prostate cancer treatment.]

International audienceAndrogen suppression clearly increases the occurrence of cardiovascular risk factors : increased body fat, dyslipidemia and type II diabetes. Thus, several studies (but not all), showed an increase in coronary artery disease but also of sudden death and ventricular arrhythmias in relation to androgen deprivation, even for a short duration. This risk is particularly important in patients with existing cardiovascular risk factors or a history of heart disease. Cardiovascular risk should be balanced with the benefit of androgen deprivation on overall survival, especially when it is proposed in adjuvant setting, combined with radiotherapy in locally advanced prostate tumors. In practice, it is recommended that patients be referred to their physician for an evaluation before starting treatment, then 3 to 6 months after starting treatment, then once a year. The initial assessment should include: a clinical examination (with measurement of blood pressure and body index) and laboratory test with full lipid profile (total cholesterol, HDL and LDL cholesterol, triglycerides) and glucose. It is also important that patients with heart disease, receive lifestyle advice and low- dose aspirin (80 mg/day)

Quantitative proteomic determination of diethylstilbestrol action on prostate cancer

International audienceDiethylstilbestrol (DES) has a direct cellular mechanism inhibition on prostate cancer. Its action is independent from the oestrogen receptors and is preserved after a first-line hormonal therapy. We aimed to identify proteins involved in the direct cellular inhibition effects of DES on prostate cancer. We used a clonogenic assay to establish the median lethal concentration of DES on 22RV1 cells. 22RV1 cells were exposed to standard and DES-enriched medium. After extraction, protein expression levels were obtained by two-dimensional differential in-gel electrophoresis (2D-DIGE) and isotope labelling tags for relative and absolute quantification (iTRAQ). Proteins of interest were analysed by quantitative RT-PCR and western blotting. The differentially regulated proteins (P$$1.3 fold; P$<$0.05). The iTRAQ analyses allowed the identification of 895 proteins. Among these proteins, 65 had a modified expression due to DES exposure (i.e., 23 overexpressed and 42 underexpressed). Most of these proteins were implicated in apoptosis and redox processes and had a predicted mitochondrial expression. Additionally, ingenuity pathway analysis placed the OAT and HSBP1 genes at the centre of a highly significant network. RT-PCR confirmed the overexpression of OAT (P50.006) and HSPB1 (P50.046)

Facteurs de risque génétiques des tumeurs prostatiques

LE KREMLIN-B.- PARIS 11-BU Méd (940432101) / SudocPARIS-BIUP (751062107) / SudocSudocFranceF

A Multicenter, Randomized, Placebo-Controlled Study Evaluating the Efficacy of a Combination of Propolis and Cranberry (\textbf\textitVaccinium macrocarpon) (DUAB\textregistered) in Preventing Low Urinary Tract Infection Recurrence in Women Complaining of Recurrent Cystitis

International audienceObjectives: The purpose of the study was to compare the efficacy of a product containing cranberry and propolis (DUAB) to placebo for reducing frequency of cystitis in women with recurrent acute cystitis. Method: A multicenter, placebo-controlled, randomized study of women aged >18 years with at least 4 episodes of cystitis in the previous 12 months was performed. The number of cystitis episodes over a 6-month follow-up was the primary end point. Results: Forty-two women were included in the cranberry + propolis group, and 43 women were in the placebo group. The mean age was 53 ± 18 years, with 6.2 ± 3.6 cystitis episodes in the previous year, with no differences between the 2 groups. The mean number of infections was lower in the propolis + cranberry group (respectively, 2.3 ± 1.8 vs. 3.1 ± 1.8). The total number of cystitis episodes in the first 3 months was lower in the propolis + cranberry group (0.7 ± 1.1 vs. 1.3 ± 1.1, p = 0.0257) after adjusting for water consumption. The mean time to onset of the first urinary tract infection (UTI) was also significantly longer in the propolis + cranberry group (69.9 ± 45.8 days vs. 43.3 ± 45.9, p = 0.0258). Tolerance to the treatments was good and comparable in both groups. Conclusions: We demonstrate for the first time that cranberry and propolis supplementation significantly reduces the incidence of UTIs during the first 3 months and delays the onset of an episode of cystitis